RRM2B and prostate adenocarcinoma: Similarly, RRM2B (nucleotide biosynthesis), PRKAA1 (AMPK signaling), and RICTOR (mTOR signaling) had widespread copy number gains exclusively in glycolytic cancers, apart from RRM2B, which had copy number gains in ~30% of evaluated PRAD patient tumor genes (Figure 4, Figures S3 and S4).